icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Can HCV be eliminated among HIV---infected MSM in Berlin?
Modeling a setting with increasing incidence and high treatment rates

 
 
  [from Jules: a key remaining barrier to eliminating HCV]
 
AASLD: INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO, 2000-2015 - (11/10/17)
 
EACS: High incidence of HCV reinfection in HIV-positive MSM in the DAA era - (10/30/17)
 
CROI: A Systematic HCV-RNA Screening in HIV+ MSM Reveals a High Number of Potential Transmitters: 5% HCV Prevalence, 17% acute HCV incidence, higher rates of condomless sex, IDU, syphillis - (03/07/17)
 
CROI: High prevalence of hepatitis C virus among HIV negative MSM in the Amsterdam PrEP project - (03/02/17)
 
AASLD: HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B - (10/26/17)
 
AASLD: Epidemiologic Impact of Expanding Chronic Hepatitis C (CHC) Treatment in People Who Inject Drug in the United States: A Mathematical Model Using Data From the C-EDGE CO-STAR Study - (11/16/17)
 
EACS: The Burden of HCV-Related Cirrhosis Among HIV/HCV Coinfected Individuals in Spain in the DAA Era: What will the battlefield look like once the battle is over? - (11/02/17)
 
Reported by Jules Levin
American Association for the Study of Liver Diseases (AASLD 2017), Washington, DC, October 20-24, 2017

1127171

1127172

1127173

1127174